Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC grew its position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 278.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 46,408 shares of the biopharmaceutical company’s stock after acquiring an additional 34,157 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Sangamo Therapeutics were worth $60,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of SGMO. BlackRock Inc. raised its position in shares of Sangamo Therapeutics by 15.4% in the third quarter. BlackRock Inc. now owns 14,264,458 shares of the biopharmaceutical company’s stock worth $69,894,000 after acquiring an additional 1,898,292 shares during the period. State Street Corp raised its position in shares of Sangamo Therapeutics by 25.3% during the 1st quarter. State Street Corp now owns 7,775,327 shares of the biopharmaceutical company’s stock worth $45,175,000 after purchasing an additional 1,570,740 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Sangamo Therapeutics by 10.5% during the 3rd quarter. Vanguard Group Inc. now owns 12,731,109 shares of the biopharmaceutical company’s stock worth $62,383,000 after purchasing an additional 1,205,951 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Sangamo Therapeutics by 52.5% during the 1st quarter. Renaissance Technologies LLC now owns 3,232,795 shares of the biopharmaceutical company’s stock worth $5,690,000 after purchasing an additional 1,113,299 shares during the last quarter. Finally, ExodusPoint Capital Management LP raised its position in shares of Sangamo Therapeutics by 496.5% during the 1st quarter. ExodusPoint Capital Management LP now owns 1,309,323 shares of the biopharmaceutical company’s stock worth $2,304,000 after purchasing an additional 1,089,804 shares during the last quarter. Institutional investors and hedge funds own 59.81% of the company’s stock.

Sangamo Therapeutics Price Performance

Sangamo Therapeutics stock opened at $0.38 on Friday. The firm has a 50 day simple moving average of $0.58 and a 200-day simple moving average of $0.98. Sangamo Therapeutics, Inc. has a 1-year low of $0.29 and a 1-year high of $3.76. The stock has a market cap of $68.23 million, a price-to-earnings ratio of -0.27 and a beta of 1.12.

Analyst Ratings Changes

SGMO has been the subject of several research analyst reports. Royal Bank of Canada restated a “sector perform” rating and set a $2.00 price target (down previously from $6.00) on shares of Sangamo Therapeutics in a research report on Friday, November 3rd. HC Wainwright reduced their price target on shares of Sangamo Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Monday, November 6th. Truist Financial restated a “hold” rating on shares of Sangamo Therapeutics in a research report on Tuesday, November 7th. Wedbush reduced their price target on shares of Sangamo Therapeutics from $16.00 to $10.00 and set an “outperform” rating for the company in a research report on Friday, August 11th. Finally, StockNews.com initiated coverage on shares of Sangamo Therapeutics in a research note on Saturday. They set a “sell” rating for the company. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Sangamo Therapeutics has an average rating of “Hold” and a consensus target price of $4.68.

Insider Activity

In other news, major shareholder Biogen Inc. sold 6,000,000 shares of the stock in a transaction that occurred on Tuesday, September 26th. The shares were sold at an average price of $0.50, for a total value of $3,000,000.00. Following the completion of the sale, the insider now owns 17,652,466 shares of the company’s stock, valued at approximately $8,826,233. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 3.00% of the company’s stock.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.